Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression

QR Code

Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression

Serkan Zincir,1 Pelin Öztürk,2 Ali Emrah Bilgen,3 Filiz İzci,4 Cihad Yükselir5 1Department of Psychiatry, Gölcük Military Hospital, Kocaeli, 2Psychiatry Clinic, Erenkoy Training and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, 3...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Zincir S, Öztürk P, Bilgen AE, İzci F, Yükselir C
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2016
Sujets:	major depression ECT the immune system cytokines Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/db22b26cdbeb40329ffcb90bfda7de6c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Number of Electroconvulsive Therapy Sessions required for Thai Psychiatric Patients: a Retrospective Study
par: Ittasakul P, et autres
Publié: (2020)

Changes in the Practice of Electroconvulsive Therapy in Poland: A Nationwide Survey Comparing Data Between 2005 and 2020
par: Antosik-Wójcińska AZ, et autres
Publié: (2021)

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder
par: Bian Z, et autres
Publié: (2021)

A review of ketamine’s role in ECT and non-ECT settings
par: Jankauskas V, et autres
Publié: (2018)

Medication management during electroconvulsant therapy
par: Zolezzi M
Publié: (2016)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
par: Wang M, et autres
Publié: (2019)

Pioglitazone could induce remission in major depression: a meta-analysis
par: Colle R, et autres
Publié: (2016)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
par: Ran S, et autres
Publié: (2020)

The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression
par: Dore Loef, et autres
Publié: (2021)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
par: Mustafa Ali, et autres
Publié: (2021)

Risk Assessment of Electroconvulsive Therapy in Clinical Routine: A 3-Year Analysis of Life-Threatening Events in More Than 3,000 Treatment Sessions
par: Vivien L. Hajak, et autres
Publié: (2021)

Prevalence and Predictors of Postictal Confusion After Electroconvulsive Therapy
par: Ittasakul P, et autres
Publié: (2021)

Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy
par: Claudia Pisanu, et autres
Publié: (2021)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
par: Hammer-Helmich L, et autres
Publié: (2018)

Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder
par: Liang JQ, et autres
Publié: (2020)

Weighted Gene Coexpression Network Analysis Identifies Specific Modules and Hub Genes Related to Major Depression
par: Zhang G, et autres
Publié: (2020)

Electroconvulsive therapy in 77-year-old patient with pacemaker: a case report
par: Mędrala T, et autres
Publié: (2018)

Identification of Gene Co-Expression Modules and Core Genes Related to Immune Disorders in Major Depression Disorder
par: Zhang L, et autres
Publié: (2021)

Sex differences in gut microbiota in patients with major depressive disorder
par: Chen JJ, et autres
Publié: (2018)

Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases
par: Fuquan Zhang, et autres
Publié: (2021)

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder
par: Chen S, et autres
Publié: (2021)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
par: Tomita T, et autres
Publié: (2016)

Predictors of Major Depressive Disorder in Older People
par: Susana Sousa, et autres
Publié: (2021)

Stimulus intensity determined by dose-titration versus age-based methods in electroconvulsive therapy in Thai patients
par: Ittasakul P, et autres
Publié: (2019)

Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study
par: Okamoto N, et autres
Publié: (2020)

Electroacupuncture plus moxibustion for major depressive disorder: A randomized, sham-controlled, pilot clinical trial
par: Mikyung Kim, et autres
Publié: (2022)

Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
par: Hashimoto T, et autres
Publié: (2015)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017)

Plasma complement component 4 increases in patients with major depressive disorder
par: Wei J, et autres
Publié: (2017)

Association between anxious distress in a major depressive episode and bipolarity
par: Sugawara H, et autres
Publié: (2019)

Elevated peripheral blood glutamate levels in major depressive disorder
par: Inoshita M, et autres
Publié: (2018)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
par: Yoshimura R, et autres
Publié: (2017)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
par: Harada E, et autres
Publié: (2017)

Assessment of current clinical practices for major depression in Japan using a web-based questionnaire
par: Hori H, et autres
Publié: (2019)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
par: Harada E, et autres
Publié: (2016)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
par: Saragoussi D, et autres
Publié: (2018)

Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
par: Roulot M, et autres
Publié: (2018)

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
par: Naghmeh Nikkheslat
Publié: (2021)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
par: Huang Q, et autres
Publié: (2016)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
par: McIntyre RS, et autres
Publié: (2021)